To effectively address the global aging trend and advance research and innovation in longevity medicine, the Global Symposium on Longevity Medicine was held at Shenzhen Lansheng Brain Hospital on August 24. The event was chaired by Professor Li Wenbin, Director of Neurotumor Comprehensive Treatment Center, Beijing Tiantan Hospital, Capital Medical University. A strong lineup of invited guests included David Boehm, President of Miskawa International Medical Center (Thailand), Huang Yuan, Director of Hong Kong Longevity Medicine Center, Boris Djordjevic, Director of 199 Longevity Clinic and Research Institute (UK), Li Juan, CEO of 199 Longevity Clinic (UK), Fan Yu, CEO of Well Beyond Bio Technology Co Pte. Ltd. (Singapore), Liu Liansheng, Chairman of Shenzhen Poka Electronic Equipment Co., Ltd., as well as Wang Yawei, Operation Director of People’s Good Doctor Platform of people.cn, Liu Feiyun, Deputy Director of Marketing Working Committee of China Anti-aging Promotion Association, and other renowned experts and business leaders in China and abroad. Mr. Zhang Jie, Chairman of the Company, was invited to attend the Symposium and made a speech as the expert.

In his speech, Mr. Zhang Jie provided a detailed overview of the core business, technological strengths, and market position of the Company. He shared forward-looking insights on addressing global aging and advancing longevity medical research and development. He highlighted that chlorogenic acid is widely found in plants, and has antioxidant, antiviral, anti-inflammatory, anti-tumor and immunomodulation effects. Notably, the Company’s ongoing clinical study of chlorogenic acid for injection against glioma is the world’s first systematic drug research and development project on chlorogenic acid monomer. The project was approved for clinical trial by NMPA in August 2013, and the clinical trial has progressed smoothly and is now poised to enter the summary stage of the clinical trial.

The Company has cooperated with Chinese top medical research institutions to clarify the main mechanism of CHA CHA is an effective differentiation inducer for many kinds of solid tumor cells, which can act on mitochondria, regulate ATP, activate relevant signals to induce tumor cell differentiation, reduce the degree of malignancy, slow down the growth of solid tumors, and decrease the metastasis and invasiveness. In addition, induction of cell differentiation decreases PD-L1 expression of cancer cells, increases the immune effector cells in the tumor microenvironment, improves the tumor immune microenvironment and ultimately inhibits or eliminates the tumor to achieve the symptomatic and curative effects. Furthermore, through systematic target fishing and validation with protein microarray technologies, an additional potential therapeutic target of CHA, acetyl-coenzyme A acetyltransferase 1 (mtACAT1), has been identified. Through cryo-electron microscopy technology at Tsinghua University, the interaction between CHA and mtACAT1 has been conclusively elucidated. Phosphorylated acetyl-coenzyme A acetyltransferase 1 can promote cell proliferation and tumor growth, whereas chlorogenic acid can inhibit mtACAT1 phosphorylation and tumor growth. mtACAT1 in the organism is also closely related to aging and the development of major chronic diseases. CHA regulates the activity of mtACAT1, which will also have great application prospects in anti-aging and chronic disease treatment.

From left to right in the front row: Wang Yawei, Operation Director of People’s Good Doctor Platform of people.cn,  Liu Liansheng, Chairman of Shenzhen Poka Electronic Equipment Co., Ltd., Zhang Jie, Chairman of Jiuzhang Biotech, David Boehm, President of Miskawa International Medical Center (Thailand), Boris Djordjevic, Director of 199 Longevity Clinic and Research Institute (UK), Professor Li Wenbin, Director of Neurotumor Comprehensive Treatment Center, Beijing Tiantan Hospital, Capital Medical University, Huang Yuan, Director of Hong Kong Longevity Medicine Center, and Fan Yu, CEO of Well Beyond Bio Technology Co Pte. Ltd. (Singapore).